ScholarIQanswers from OpenAlex
Mitsubishi Tanabe Pharma Corporation
FunderResearch funding and supported work
Mitsubishi Tanabe Pharma Corporation is a funder indexed in ScholarIQ from OpenAlex.
What is known about Mitsubishi Tanabe Pharma Corporation?
ScholarIQrecord summary
Japanese pharmaceuticals company
How many works does Mitsubishi Tanabe Pharma Corporation have?
ScholarIQindexed works
Mitsubishi Tanabe Pharma Corporation has 2,459 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
What is the OpenAlex record for Mitsubishi Tanabe Pharma Corporation?
ScholarIQopenalex
The OpenAlex for Mitsubishi Tanabe Pharma Corporation is on the source record.
What is the ROR of Mitsubishi Tanabe Pharma Corporation?
ScholarIQror
The ROR for Mitsubishi Tanabe Pharma Corporation is on the source record.
What are the most-cited papers on Mitsubishi Tanabe Pharma Corporation?
ScholarIQmost cited works
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
Helen M. Colhoun, Ildiko Lingvay, Paul Brown, John Deanfield, Kirstine Brown‐Frandsen, Steven E. Kahn, Jorge Plutzky, Koichi Node, Alexander Parkhomenko, Lars Rydén, John Wilding, Johannes F.E. Mann, Katherine R. Tuttle, Thomas Idorn, Naveen Rathor, A. Michael Lincoff
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial
Natalie Staplin, Richard Haynes, PK Judge, Christoph Wanner, Julie Green, Jonathan Emberson, David Preiss, KJ Mayne, SYA Ng, Emily Sammons, Dandan Zhu, Michael Hill, W. Grant Stevens, Karl Wallendszus, S Brenner, AK Cheung, Zhihong Liu, J Li, LS Hooi, Wenjun Liu, Takashi Kadowaki, Masaomi Nangaku, Adeera Levin, David Z.I. Cherney, Aldo P. Maggioni, Roberto Pontremoli, Rajat Deo, Shinichi Goto, Xavier Rosselló, Katherine R. Tuttle, Dominik Steubl, Michaela Petrini, Siegfried Seidi, Martin Landray, Colin Baigent, WG Herrington, Sharirose Abat, Riaz Rahman, Rizna Abdul Cader, MI Abdul Hafidz, MZ Abdul Wahab, NK Abdullah, Talal Abdulsamad, Masami Abe, Ned Abraham, Sarah Acheampong, P Achiri, JA Acosta, A A Adeleke, Vicki Adell, R Adewuyi-Dalton, Nihad Adnan, A Africano, Mohsen Agharazii, Frank G. Aguilar, A Aguilera, M Ahmad, MK Ahmad, NA Ahmad, NH Ahmad, NI Ahmad, Norazinizah Ahmad Miswan, H Ahmad Rosdi, Iffat Ahmed, Sofia B. Ahmed, Sofia B. Ahmed, Joan Aiello, Alastair Aitken, R AitSadi, Sendogan Aker, S Akimoto, Akinwande A. Akinfolarin, S. Akram, Federico Alberici, Christian Albert, Luke Aldrich, M Alegata, Lacy M. Alexander, S Alfaress, Mohammad Alhadj Ali, A Ali, A Ali, Radica Z. Alicic, Arta Aliu, Ricardo López Almaraz, Rashid Almasarwah, Jussara Carnevale de Almeida, Alessia Aloisi, Laith Al‐Rabadi, Mark Dominik Alscher, Pedro Álvarez, Bader Al-Zeer, M. Ochoa de Olza Amat, Christopher S. Ambrose, Hany Ammar, Yu An, L Andriaccio, K Ansu, A Apostolidi, N. Arai
Double-Blind, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Eplerenone in Japanese Patients With Chronic Heart Failure (J-EMPHASIS-HF)
Hiroyuki Tsutsui, Hiroshi Ito, Masafumi Kitakaze, Issei Komuro, Toyoaki Murohara, Tohru Izumi, Kenji Sunagawa, Yoshio Yasumura, Masafumi Yano, K. Yamamoto, Tsutomu Yoshikawa, Takayoshi Tsutamoto, Junwei Zhang, Akifumi Okayama, Yoshihiko Ichikawa, Kazuhiro Kanmuri, Masunori Matsuzaki, for the J-EMPHASIS-HF Study Group
Effects of canagliflozin on myocardial infarction: a <i>post hoc</i> analysis of the CANVAS programme and CREDENCE trial
Jie Yu, Jingwei Li, Phillip J Leaver, Clare Arnott, Mark D. Huffman, Jacob A. Udell, Vlado Perkovic, Kenneth W. Mahaffey, Dick de Zeeuw, Greg Fulcher, David R. Matthews, Wayne Shaw, Norman Rosenthal, Bruce Neal, Gemma A. Figtree